Ellen J. Scherl, MD

Articles by Ellen J. Scherl, MD

Key Takeaways for Ulcerative Colitis Management

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

July 12th 2022

Experts in gastroenterology share take-home messages for the management of ulcerative colitis.

Clinical Pearls for the Treatment of Ulcerative Colitis

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

July 12th 2022

David P. Hudesman, MD; Marla Dubinsky, MD; Ellen J. Scherl, MD; and Miguel Regueiro, MD, provide advice for physicians treating patients with ulcerative colitis.

Future Treatment Paradigms in Ulcerative Colitis

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

July 6th 2022

Drs David P. Hudesman, Ellen J. Scherl, Marla Dubinsky, and Miguel Regueiro, explore novel therapies in the pipeline and discuss approaches to optimizing sequencing and treatment selection for ulcerative colitis.

Sequencing Therapies in Ulcerative Colitis

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

July 6th 2022

Experts in gastroenterology discuss their approach to sequencing therapies in ulcerative colitis, considering safety, efficacy, and access to various treatment regimens and comment on challenges physicians may face when incorporating new therapies into clinical practice.

Ozanimod in Ulcerative Colitis

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

June 28th 2022

Ellen J. Scherl, MD, reviews data from the phase 3 True North study evaluating the use of ozanimod as induction and maintenance therapy for moderate to severe ulcerative colitis, and the panel shares their experience with ozanimod in clinical practice.

Challenges in UC Treatment

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

June 28th 2022

Ellen J. Scherl, MD, leads a discussion on challenges faced with traditional ulcerative colitis treatments.

Switching Therapies in Ulcerative Colitis

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

June 21st 2022

David P. Hudesman, MD, and expert panelists provide insight on optimizing the sequencing of therapies in ulcerative colitis and determining when a change in treatment is needed.

Role of JAK Inhibitors and S1P Receptor Modulators for UC Treatment

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

June 21st 2022

Marla Dubinsky, MD, discusses the role of S1P receptor modulators and JAK inhibitors for the treatment of ulcerative colitis.

UC Treatment: Anti-integrin Antibodies and Anti-interleukins

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

June 14th 2022

David P. Hudesman, MD, reviews the use of anti-integrin and anti-interleukin therapies for the management of ulcerative colitis.

Using 5-ASAs and Steroids for UC Treatment

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

June 14th 2022

Ellen J. Scherl, MD, comments on the limited role of mesalamine and steroids for moderate-to-severe ulcerative colitis treatment.

Approaching Ulcerative Colitis Treatment Selection

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

June 7th 2022

Marla Dubinsky, MD, emphasizes the role of shared decision-making and patient goals of therapy when approaching treatment selection for ulcerative colitis.